Provider review · Updated October 15, 2026
Ivy Rx tirzepatide microdose review: follow the prescription beyond the catalog
Ivy names two ingredients under one microdose offer. Its price, quality statements and customer survey each answer a different question.
Editorial source review, with no clinician sign-off or firsthand treatment experience claimed.
Ivy Rx gives its microdose product a dedicated page, separate from its standard GLP-1 injection listing. That makes the service easier to locate, but the microdose title still covers more than one medicine. The useful reading sequence is to identify the proposed prescription first, then connect it to the price, clinical responsibility and evidence being presented.
We checked Ivy’s microdose listing, weight-loss catalog and refund policy on October 15, 2026. This is a review of public records, without a purchase, pharmacy inspection, patient interview or tested consultation. The site’s separate CoreAge promotion is disclosed and does not supply evidence about Ivy’s service or comparative treatment results.
In this article
One microdose page names two active ingredients
The Ivy microdose listing describes compounded injections containing tirzepatide or semaglutide. It does not say that every visitor will receive tirzepatide. Its separate weight-loss catalog also contains standard GLP-1 injections, other medicines and supplements. Those neighboring products should not be folded into the microdose offer.
The first individual record needed is the clinician’s proposed medication, including its ingredients and preparation. Our program-record comparison explains how to distinguish a catalog from a prescription. We can establish that Ivy advertises a tirzepatide-containing microdose option, but we cannot identify the final formulation, pharmacy or prescribed amount for a particular patient from the category page.
The starting price is not a complete tirzepatide quote
The microdose page advertises a starting price of $69 with four doses per month and describes pricing that does not change with dose. The catalog distinguishes this from a $77 starting figure for its other GLP-1 listing. Neither number alone establishes the total cost of a selected tirzepatide plan, its required commitment or its renewal date.
We did not complete the intake or checkout to obtain an individual quote. Save the medicine choice, amount payable, supply period, shipping terms and recurring charge together. Our price-record guide shows why moving a headline between different product records produces an unreliable comparison, even when the same company publishes both prices.
Quality claims need the record for the dispensed product
The product page describes preparation in state-licensed pharmacies and independent laboratory verification. It lists potency, sterility, endotoxin and pH checks, including a stated periodic potency-testing interval. These are the company’s descriptions of its process. We did not inspect testing certificates, batch records or the actual medicine a patient would receive.
Our compounding-record guide distinguishes a pharmacy license, a laboratory result and regulatory product approval. FDA’s GLP-1 guidance explains that compounded medicines are not FDA-approved. A reference to a registered laboratory cannot stand in for approval of the finished preparation, and a general testing badge does not establish which certificate covers a particular dispensed batch.
A customer survey is not an exact-product trial
Ivy’s microdose page says 82.6 percent of new customers reported weight loss at their first check-in and attributes the figure to internal customer survey data. The reviewed description does not establish that this population consisted specifically of tirzepatide microdose users, nor does it provide enough detail to independently assess response rates, timing or the amount of change.
The result should remain attached to that survey description. It does not establish an expected outcome for a new patient. Our trial-regimen guide explains why ingredient names, schedules and populations matter when interpreting evidence. We have not converted provider-hosted testimonials or a changing review-platform score into an editorial efficacy rating.
An eligibility calculator does not make the clinical decision
The microdose listing includes a BMI calculator that directs readers toward different product pathways. It also advertises an online questionnaire, same-day clinician review and access without routine labwork. Those are descriptions of the advertised intake process, not a complete account of how an individual history will be assessed.
A clinician still needs to determine whether treatment is appropriate and whether additional information is necessary. We did not submit health details or test approval speed. The DrHouse records review illustrates the broader point: access to a consultation does not promise a particular prescription. A calculator category should not be read as an approved indication or a personalized medical recommendation.
Follow-up access should connect to the responsible clinician
The Ivy FAQ says patients can securely message their care providers through the patient portal and describes live support and a mobile app. The footer says Ivy arranges an evaluation with a qualified professional, with prescriptions filled at a partner pharmacy if approved. That establishes the advertised division of roles, while leaving the assigned professionals unresolved.
Before enrolling, establish which contact handles clinical questions, refill decisions and pharmacy concerns. The reviewed page does not give a guaranteed clinical response time or show how an unresolved concern is escalated. Those missing details are limits of the public record, not evidence that support is absent. We did not evaluate individual licenses or conduct a service-response test.
The brief return policy leaves subscription details to confirm
Ivy’s refund page says it cannot accept product returns and invites customers with concerns to contact support. That brief statement does not, by itself, define the selected microdose plan’s renewal deadline, cancellation procedure or refund treatment before medication fulfillment. We cannot infer those conditions from the existence of a contact address.
The public record supports a limited conclusion: Ivy advertises compounded microdose injections with named ingredient options, a starting price and a care pathway. A useful final comparison still needs the selected prescription, accepted billing agreement, identifiable pharmacy and follow-up arrangements. Keep those records together instead of treating a quality badge, survey percentage or starting price as a substitute for the whole offer.
Sources behind this reading
- Ivy Rx: Microdose GLP-1 Injections ↗Provider product and care claims · Checked 2026-10-15
- Ivy Rx: Weight-loss treatment catalog ↗Provider catalog and starting prices · Checked 2026-10-15
- Ivy Rx: Refund Policy ↗Provider return policy · Checked 2026-10-15
- FDA: Concerns with Unapproved GLP-1 Drugs Used for Weight Loss ↗Regulatory guidance · Checked 2026-10-15